To test if targeting the VEGF-axis could impact secondary spread of tumor cells beyond SLNs, we conducted multiple large cohort experiments in which dosing of anti-NRP2B, anti-VEGF-C, or anti-VEGF-A antibodies initiated after primary tumor resection at day 12, then quantified metastases within lungs at day 26. This evidence concerns the gene VEGFA and neoplasm.